Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

80P - Oncolytic adenovirus type 3 coding for CD40L facilitates dendritic cell therapy of prostate cancer in humanized mice and patient samples

Date

09 Dec 2020

Session

e-Poster Display Session

Presenters

Saru Basnet

Citation

Annals of Oncology (2020) 31 (suppl_7): S1441-S1451. 10.1016/annonc/annonc392

Authors

S. Basnet, S. Zafar, I.M. Launonen, D. Quixabeira, J.M. Santos

Author affiliations

  • University of Helsinki, Helsinki/FI
More

Abstract 80P

Background

Dendritic cells (DCs) are vital antigen-presenting cells and they are a central part of the immune system. They play a crucial role in detection and elimination of pathogens and cancer cells. DCs based vaccination is a safe and promising approach in cancer immunotherapy. Tumor microenvironment derived immunosuppression inhibits and weakens the function of DCs by hampering their maturation and activation. The outcomes of human clinical trial with DCs monotherapy have shown limited efficacy. This study hypothesized that activated DCs would further activate tumor specific cytotoxic T cells and result in therapeutic antitumor immune responses. Oncolytic viruses kill cancer cells by replicating selectively at tumor site. They enhance antitumor immunological effects by releasing tumor epitopes in the presence of pathogens and danger associated signals.

Methods

In this study, we used a fully serotype 3 oncolytic adenovirus (Ad3-hTERT-CMV-hCD40L; TILT-234) expressing human CD40L for the stimulation of DC and induction of antitumor immune response in prostate tumor microenvironment. The therapeutic benefits of Ad3-hTERT-CMV-hCD40L virus and DCs was evaluated in vivo and ex vivo. A Humanized mouse model was used to determine antitumor efficacy in vivo. The cytotoxic ability of viruses is evaluated ex vivo using single cell digestion of tumor samples obtained from patients.

Results

Enhanced antitumor responses and improved cancer specific survival is observed when prostate tumors were treated with Ad3-hTERT-CMV-hCD40L virus and DCs in vivo. Complete cells killing was evident ex vivo when tumors were treated with virus using MTS viability assay. Upregulated expression of DCs maturation marker such as CD86/CD83/CD80 was evident when patient samples were treated with virus indicating virus induced DCs maturation. A prominent increase in pro-inflammatory cytokines was observed ex vivo indicating the virus induced immunostimulatory modulation in the tumor.

Conclusions

Ad3-hTERT-CMV-hCD40L virus can modulate the immunosuppressive tumor microenvironment ex vivo in patient samples. Importantly, this virus could enable successful dendritic cell therapy in prostate cancer models and patient explants.

Legal entity responsible for the study

Cancer Gene Therapy Group.

Funding

KLTO (Doctoral School for Clinical Research programme at the University of Helsinki), Jane and Aatos Erkko Foundation, HUCH Research Funds (VTR), Sigrid Juselius Foundation, Finnish Cancer Organizations, University of Helsinki, Novo Nordisk Foundation, Päivikki and Sakari Sohlberg Foundation and TILT Biotherapeutics Ltd. Albert Ehrnrooth and Karl Fazer for research support.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.